lines (avian embryonic derived stem cell lines) for the production of
GeoVax's MVA (Modified Vaccinia Ankara) based HIV/AIDS vaccines.
Results obtained from Vivalis and GeoVax demonstrated that EBx(R) cell
technology is possibly a more economical alternative to chicken
embryonic fibroblasts (CEFs) for the replication of GeoVax specific
recombinant MVA based AIDS vaccines. Simultaneously, GeoVax's promising
results in preclinical trials as well as encouraging and positive
immune response data from two ongoing human trials provided the impetus
for accelerating clinical evaluations of GeoVax's vaccines and for
considering the EBx(R) cell platform in industrial vaccine production.
Vivalis and GeoVax collaborations focus on scaling-up MVA based
HIV/AIDS vaccine production processes in EBx(R) cells. In addition,
Vivalis plans preparation of an EBx(R) platform Biological Master File
for filing with the FDA. In parallel, GeoVax is evaluating plans for an
immunogenicity comparability study of GeoVax's MVA based HIV/AIDS
vaccines produced in CEFs and those produced in EBx(R) cells. This
information may be presented in a pre-IND meeting with the FDA
concerning potential use of this cell line.
Donald Hildebrand, Chief Executive Officer of GeoVax, commented,
"Recent developments at GeoVax encourage and excite us as we continue
working toward our ultimate goal of making available a safe and effective
vaccine for the prevention of AIDS. We are particularly encouraged by the
recent accelerated start date of our two new human clinical trials,
resulting primarily from the excellent safety and anti-HIV immune response
results obtained to date from our ongoing 1/10th and full dose vaccine
trials. We are also pleased with the positive response to our progress at
GeoVax as reflected by
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.